ClearPoint Neuro stockholders approve authorized share reduction from 200M to 80M

ClearPoint Neuro, Inc.

Authorized common shares reduced from 200M to 80M via Certificate of Amendment.
Eight directors elected, including Joseph Burnett, R. John Fletcher, and Matthew Klein.
Cherry Bekaert LLP ratified as independent auditor for FY 2022; 15.8M for, 19.6K against.
Fourth Amended and Restated 2013 Incentive Compensation Plan approved (8.7M for).
Advisory vote on executive compensation approved with 8.6M for, 887K against.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.